Inhaled drug shows promise for Long-Term PAH control
NCT ID NCT04816604
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This study looks at the long-term safety of an inhaled medication called GB002 for people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. Participants had already taken GB002 in an earlier study and will continue treatment while researchers monitor side effects and track how far they can walk in six minutes. The goal is to see if the drug remains safe and helps control the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HP Hôpital de Bicêtre
Le Kremlin-Bicêtre, 94270, France
-
Cleveland Clinic Florida
Weston, Florida, 33331, United States
-
DRK Kliniken Berlin
Berlin, Germany
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, 39008, Spain
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
INTEGRIS Baptist Medical Center, Inc.
Oklahoma City, Oklahoma, 73112, United States
-
Imperial College Healthcare NHS Trust - Hammersmith Medicines Research Limited
London, United Kingdom
-
Klinik für Pneumologie, Klinisches Studienzentrum Medizinische Hochschule
Hanover, 30625, Germany
-
Klinik und Poliklinik f. Innere Medizin II Universitätsklinikum Regensburg
Regensburg, 93053, Germany
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Medical Corporation
Santa Barbara, California, 93105, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
New York Presbyterian Hospital - Weill Cornell Medicine
New York, New York, 10065, United States
-
Norton Pulmonary Specialists
Louisville, Kentucky, 40202, United States
-
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
-
Royal Papworth Hospital NHS Foundation Trust
Cambridge, CB2 OAY, United Kingdom
-
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Thoraxklinik-Heidelberg gGmbH
Heidelberg, 69126, Germany
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik IV und V
Giessen, Germany
-
University of California, Davis Medical Center
Sacramento, California, 95817, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Utah Health
Salt Lake City, Utah, 84132, United States
-
Všeobecná fakultní nemocnice v Praze
Prague, 128 08, Czechia
Conditions
Explore the condition pages connected to this study.